# Safety and Efficacy of Pimavanserin in Adults With Parkinson's Disease and Depression

> **NCT03482882** · PHASE2 · COMPLETED · sponsor: **ACADIA Pharmaceuticals Inc.** · enrollment: 47 (actual)

## Conditions studied

- Treatment of Depression in Adults With Parkinson's Disease (PD)

## Interventions

- **DRUG:** Pimavanserin

## Key facts

- **NCT ID:** NCT03482882
- **Lead sponsor:** ACADIA Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-09
- **Primary completion:** 2019-07-09
- **Final completion:** 2019-07-24
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2020-08-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03482882

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03482882, "Safety and Efficacy of Pimavanserin in Adults With Parkinson's Disease and Depression". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT03482882. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*